Navigation Links
GeneGo Kicks Off The MetaMiner Stem Cell Project With Industry and Academics
Date:9/1/2009

ST. JOSEPH, Mich., Sept. 1 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that it launched a collaborative development project on systems biology of stem cells with global pharmaceutical companies and leading academic centers as members. The 24-month project aims to create a comprehensive "knowledge base" on development and biology of different types of stem cells. The knowledge base will be supported by GeneGo's MetaDiscovery tools and applied in experimental research on stem cells and human diseases.

"We are really excited about this project," said Yuri Nikolsky, CEO of GeneGo. "Although one of the hottest areas of life science, no systematic effort was done on methodical annotation of current experimental knowledge on stem cells, and we intend to fill this gap. Understanding the biology of embryonic adult and neoplastic stem cells is key in both drug discovery and fundamental research in many fields from embryology and ontogenesis to cancer and diabetes."

"We are very glad to be able to attract an excellent team of members for the cause," said Julie Bryant, GeneGo's VP of Business Development. "An industry-academia consortium model fits well with our development objectives in such a complex and controversial field. We believe that the members will see a strong positive return on their investment within several months from the project's launch."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery((TM)) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.4((TM)), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.4((TM)) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase((TM)) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GeneGo Donates Proprietary Cytokine Pathway Maps to ISICR
2. Cardiff University Becomes a GeneGo Center of Excellence
3. Childrens Memorial Research Center, Chicago Becomes a Member of GeneGos MetaMiner Stem Cell Partnership Program
4. GeneGo Announces Systems Tox Relationship With Entelos
5. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
6. Queensland Facility for Advanced Bioinformatics (QFAB) Becomes a GeneGo Center of Excellence for the Asia Pacific Region
7. University of Glasgow Becomes a Member of GeneGos MetaMiner Stem Cell Partnership Program
8. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
9. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
10. The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology
11. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Ann Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... between 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 ... hosted by a MichBio member organization. They provide an opportunity to interact with peers, ...
(Date:2/16/2017)... CALABASAS, Calif. , Feb. 16, 2017 /PRNewswire/ ... on developing groundbreaking therapies to treat severe neurological ... in children treated with AGT-181, the company,s investigational ... syndrome (also known as mucopolysaccharidosis type I, or ... Phase 2 proof-of-concept (POC) study, presented today at ...
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced ... professor and Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at ... practicing female physician suffering from degenerative disc disease with radiculomyelopathy, as a result ...
Breaking Biology Technology:
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic (IVD) ... mergers and acquisitions (M&A), and Kalorama Information expects that ... acquisitions have been shifting. Generally, uncertainty in reimbursement and ... the U.S. has changed the acquisitions landscape. Instead of ... in companies buying partners outside of their home country ...
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
Breaking Biology News(10 mins):